ClinicalTrials.gg
CompletedNCT01874522Updated Sep 5, 2024

Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI

A Phase 1 interventional study of TAS-102 tablets and TAS-102 oral solution in Advanced Solid Tumors (Excluding Breast Cancer), sponsored by Taiho Oncology, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-05.

Sponsored by Taiho Oncology, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to compare the bioavailability of TAS-102 tablets to an oral solution containing equivalent amounts FTD and TPI.

Read the detailed description

This is a Phase 1, open-label, randomized, 2-sequence, 3-period crossover study evaluating the relative bioavailability of TAS-102 tablets compared to an oral solution in patients with advanced solid tumors. This study will be conducted in 2 parts. The crossover bioavailability part will be followed by an extension conducted with TAS-102 tablets only.

02

Conditions studied

  • Advanced Solid Tumors (Excluding Breast Cancer)

Browse trials for

Keywords

  • Advanced solid tumors (excluding breast cancer) for which no standard therapy exists
03

In context

Breast Neoplasms

14,840 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

This study's enrollment of 46 is below the median of 72 across 10,910 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Taiho Oncology, Inc. is the lead sponsor of 66 studies on the registry; 9 are open to participants now.

Of its 25 completed or terminated interventional studies of FDA-regulated products, 13 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has provided written
  2. Has advanced solid tumors (excluding breast cancer) for which no standard therapy exists
  3. performance status of 0 or 1
  4. Is able to take medications orally
  5. Has adequate organ function (bone marrow, kidney and liver)
  6. Women of must have a negative pregnancy test and must agree to adequate if conception is possible. Males must agree to adequate birth control.

Exclusion criteria

Exclusion Criteria:

  1. Has had certain other recent treatment e.g. anticancer therapy, received agent, within the specified time frames prior to study drug administration
  2. Certain serious illnesses or medical condition(s)
  3. Has had either partial or total gastrectomy
  4. Has unresolved toxicity of greater than or equal to Grade 2 attributed to any prior therapies
  5. Known sensitivity to TAS-102 or its components
  6. Is a pregnant or lactating female
  7. Refuses to use an adequate means of (including male patients)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    TAS-102 tablets

    Drug: TAS-102 tablets

  • Experimental
    TAS-102 oral solution

    Drug: TAS-102 oral solution

Interventions

  • DrugTAS-102 tablets

    Crossover bioavailability part: 60 mg/dose, orally, up to 2 single doses separated by 1-week washout. Extension part: 35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.

  • DrugTAS-102 oral solution

    60 mg/dose, orally, up to 2 single doses separated by 1-week washout

06

What researchers measure

Primary outcomes

  1. Extent of absorption of FTD and TPI following oral administration of TAS 102 tablets or oral solution (Cmax)

    Pharmacokinetic samples are taken on Day 1 of Periods 1, 2, and 3.

    Time frame: Day 1 of Periods 1, 2, and 3

  2. Extent of absorption of FTD and TPI following oral administration of TAS 102 tablets or oral solution (AUC0-last)

    Pharmacokinetic samples are taken on Day 1 of Periods 1, 2, and 3.

    Time frame: Day 1 of Periods 1, 2, and 3

  3. Extent of absorption of FTD and TPI following oral administration of TAS 102 tablets or oral solution (AUC0-inf )

    Pharmacokinetic samples are taken on Day 1 of Periods 1, 2, and 3.

    Time frame: Day 1 of Periods 1, 2, and 3

Secondary outcomes

  1. Tmax of FTD, TPI, and metabolites of FTD following administration of TAS 102 tablet and oral solution

    Pharmacokinetic samples are taken on Day 1 of Periods 1, 2, and 3.

    Time frame: Day 1 of Periods 1, 2, and 3

  2. T1/2 of FTD, TPI, and metabolites of FTD following administration of TAS 102 tablet and oral solution

    Pharmacokinetic samples are taken on Day 1 of Periods 1, 2, and 3.

    Time frame: Day 1 of Periods 1, 2, and 3

  3. CL/F of FTD and TPI following administration of TAS 102 tablet and oral solution

    Pharmacokinetic samples are taken on Day 1 of Periods 1, 2, and 3.

    Time frame: Day 1 of Periods 1, 2, and 3

  4. Vd/F of FTD and TPI following administration of TAS 102 tablet and oral solution

    Pharmacokinetic samples are taken on Day 1 of Periods 1, 2, and 3.

    Time frame: Day 1 of Periods 1, 2, and 3

  5. Cmax of metabolites of FTD following administration of TAS 102 tablet and oral solution

    Pharmacokinetic samples are taken on Day 1 of Periods 1, 2, and 3.

    Time frame: Day 1 of Periods 1, 2, and 3

  6. AUC0-last of metabolites of FTD following administration of TAS 102 tablet and oral solution

    Pharmacokinetic samples are taken on Day 1 of Periods 1, 2, and 3.

    Time frame: Day 1 of Periods 1, 2, and 3

  7. AUC0-inf of metabolites of FTD following administration of TAS 102 tablet and oral solution

    Pharmacokinetic samples are taken on Day 1 of Periods 1, 2, and 3.

    Time frame: Day 1 of Periods 1, 2, and 3

  8. Safety monitoring including adverse events, vital signs, and laboratory assessments

    Standard safety monitoring and grading using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) will be used.

    Time frame: Through 30 days following last administration of study medication or until initiation of new anticancer treatment

  9. Tumor assessments using Response Evaluation Criteria in Solid Tumors (RECIST)

    Time frame: Every 8 weeks during the extension period through Cycle 6 (ie, through 24 weeks). Thereafter, assessments will be performed at least every 12 weeks according to site standard of care, until at least one of the treatment discontinuation criteria is met.

07

Study locations

1 site
  • Scottsdale Healthcare
    Scottsdale, Arizona 85258, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2013, a primary completion of Aug 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2013
First posted
Jun 11, 2013
Start
Jul 2013
Primary completionActual
Aug 2015
CompletionActual
Nov 2015
Last update
Sep 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01874522
Responsible party
Sponsor
First posted
Jun 11, 2013
Start date
Jul 2013
Primary completion
Aug 2015
Completion
Nov 2015
Last update
Sep 5, 2024

Study contacts

Daniel Von Hoff, MD
principal investigator · Scottsdale Healthcare

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion